Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.19
-0.8%
$1.27
$0.86
$3.78
$260.29M0.313.27 million shs1.38 million shs
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
$3.26
-3.6%
$3.99
$2.25
$8.54
$305.01M2.121.23 million shs1.37 million shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.21
$0.72
$6.24
$258.25M2.27927,189 shsN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.26
-0.8%
$1.39
$1.12
$2.55
$61.31M0.436,369 shs68,347 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
0.00%+0.85%-7.75%-17.36%-42.79%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
0.00%+17.65%-28.06%+20.26%-48.02%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%+0.25%+0.25%+387.09%-10.91%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-5.26%-9.68%+1.61%-10.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3.0124 of 5 stars
4.51.00.00.00.63.30.6
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
1.6455 of 5 stars
3.42.00.00.00.60.80.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.42 of 5 stars
4.24.00.00.01.92.50.0
MediciNova, Inc. stock logo
MNOV
MediciNova
1.8494 of 5 stars
3.82.00.00.00.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$8.44609.62% Upside
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
2.86
Moderate Buy$17.00421.63% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00455.56% Upside

Current Analyst Ratings Breakdown

Latest MNOV, CMPS, ALLO, and INZY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/23/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ In-Line$11.00 ➝ $6.00
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
5/27/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$12.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/15/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K13,014.44N/AN/A$2.01 per share0.59
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$2.26 per shareN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M61.80N/AN/A$1.07 per share1.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$155.12M-$1.99N/AN/AN/AN/A-81.75%-59.42%7/30/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)

Latest MNOV, CMPS, ALLO, and INZY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/13/2025Q1 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.28N/A-$0.28$0.00 millionN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/8/2025Q1 2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$0.47-$0.44+$0.03-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.71
9.71
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
0.11
10.18
10.18
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66

Institutional Ownership

CompanyInstitutional Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
46.19%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
3.93%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.73 million189.86 millionOptionable
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
12093.56 million89.89 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable

Recent News About These Companies

MediciNova says first patient enrolled in EAP trial to evaluate MN-166
MediciNova Inc.
MediciNova provides update in letter to stockholders
MediciNova granted Notice of Allowance for MN-001 patent by USPTO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.19 -0.01 (-0.83%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.19 0.00 (0.00%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

COMPASS Pathways stock logo

COMPASS Pathways NASDAQ:CMPS

$3.26 -0.12 (-3.58%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$3.26 +0.00 (+0.03%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.26 -0.01 (-0.79%)
As of 07/3/2025 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.